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ABSTRACT
Introduction A key priority for the UK National Health 
Service and patients is to ensure that medicines are 
used safely and effectively. However, medication 
changes are not always optimally communicated and 
implemented when patients transfer from hospital 
into community settings. Heart failure is a common 
reason for admission to hospital. Patients with heart 
failure have a high burden of morbidity, mortality 
and complex pharmacotherapeutic regimens. The 
Improving the Safety and Continuity Of Medicines 
management at Transitions of care programme 
comprises a cluster randomised controlled trial which 
will test the effectiveness of a complex behavioural 
intervention aimed at improving medications 
management at the interface between hospitals 
discharge and community care. We will conduct a 
rigorous process evaluation to inform interpretation 
of the trial findings, inform implementation of the 
intervention on a wider scale and aid dissemination of 
the intervention.
Methods and analysis The process evaluation will 
be conducted in six purposively selected intervention 
sites (ie, hospital trusts and associated community 
pharmacies) using a mixed- methods design. Fidelity 
and barriers/enablers of implementation of the 
Medicines at Transitions Intervention (MaTI) will be 
explored using observation, interviews (20 patients, 
40 healthcare professionals), surveys and routine 
trial data collection on adherence to MaTI. A parallel 
mixed analysis will be applied. Qualitative data will 
be thematically analysed using Framework analysis 
and survey data will be analysed descriptively. Data 
will be synthesised, triangulated and mapped to 
the Consolidated Framework for Implementation 
Research where appropriate. The process evaluation 
commenced on June 2018 and is due to end on 
February 2021.
Ethics and dissemination Approved by Research 
Ethics Committee and the UK Health Research 
Authority REC: 18/YH/0017/IRAS: 231 431. Findings 
will be disseminated via academic and policy 
conferences, peer- reviewed publications and social 
media.
Trial registration number ISRCTN66212970.
INTRODUCTION
Heart failure presents a major challenge to 
healthcare systems globally.1 In the UK, it 
is thought to affect the lives of over 920 000 
people.2 In a study of four million individ-
uals, heart failure cases have been found to 
increase 12% from 2002 to 2014.3 Myocardial 
infarction has been identified as a risk for 
heart failure.4 Heart failure is treated by a 
combination of medication, lifestyle changes 
and interventional surgery depending on the 
severity of the condition. Typically, the phar-
macological treatment pathway involves a 
combination of medicines that are titrated to 
the optimal level that patients can tolerate. If 
not managed well (or if the patient has not 
been diagnosed and treated in primary care) 
they may be admitted to hospital for treat-
ment and to be stabilised. Approximately 
Strengths and limitations of this study
 ► An evaluation of a cluster randomised controlled trial 
of a complex behavioural intervention for a high pri-
ority healthcare issue.
 ► Views of patients and health professionals working 
across both primary and secondary care.
 ► A key strength is our mixed methods and the flex-
ibility of our approach in light of emerging issues 
from the study and the shifts in healthcare practice 
and policy.
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5% of all emergency hospital admissions are for heart 
failure.5 Ongoing treatment plans following discharge 
from hospital may not be fully implemented due to fail-
ures in communication between healthcare providers 
or a lack of specialist staff in the community.6 7 Patients 
may not understand their medicines, what they are for 
and why they need to take them because, for example, 
medical language may create a gap in patients’ under-
standing.8 Patients may therefore deteriorate, which can 
result in a readmission to hospital or death.9
The Improving the Safety and Continuity Of Medicines 
management at Transitions of care study
Improving the Safety and Continuity Of Medicines 
management at Transitions of care (ISCOMAT) is a 5- year 
National Institute for Health Research (NIHR)- funded 
research programme, which aims to optimise the way heart 
failure patients are supported with their medicines when 
they move from hospital to home. This may contribute to 
improving patients’ health through helping them better 
understand and use their medicines. ISCOMAT also aims 
to improve the way health professionals work together in 
order to improve communication and optimise medicines 
use when patients return home. Similar international 
studies have examined patient- centred care transitions 
for patients hospitalised for heart failure and found clin-
ical outcomes did not improve. ISCOMAT is designed for 
the UK health system and may show improvements in clin-
ical outcomes in this setting.10 In earlier work packages, 
we explored the resilience of the medicines management 
pathway for heart failure and then used Experienced 
Based Co- Design to develop the Medicines at Transitions 
Intervention (MaTI) with patients and professionals.8 11 
The MaTI was designed to make best use of medicines 
and reduce harm through: the provision of informa-
tion to the patient; enhanced communication between 
hospital and the patient’s community pharmacist; and 
increased engagement of the community pharmacist post 
discharge. We have provided limited information about 
the intervention here to avoid potential contamination 
of the ongoing trial. A more detailed description of the 
MaTI intervention will be published alongside feasibility 
testing. The cluster randomised controlled trial is testing 
the effectiveness of the MaTI. Patients will be recruited 
from cardiology wards in 42 acute National Health 
Service trusts across England, over approximately 12 
months. The recruitment target is 50 patients from each 
cardiology ward (target n=2100 patients in total). Sites are 
randomised to either treatment as usual or to the MaTI. A 
site coordinator is responsible for organising the trial and 
implementation of the MaTI at each site.
The process evaluation
Process evaluations are increasingly carried out alongside 
randomised controlled trials.12 13 They are particularly well 
suited to trials of complex interventions in multiple sites 
where the intervention may be implemented differently 
throughout sites and help us to understand more about 
the practical problems encountered and how they were 
resolved. We will follow the Medical Research Council 
(MRC) recommendations and guidance on process eval-
uations.13 The process evaluation will examine the effect 
of organisational context and setting on intervention 
delivery, and how the intervention is best implemented. 
There are no predefined methods that a process evalu-
ation must adopt although they typically involve mixed 
methods.14 15 Although the process and outcomes evalu-
ation will be conducted by separate teams, the trial and 
process evaluation teams will meet regularly to have 
oversight.
Aims and objectives
The aims of the process evaluation are to inform inter-
pretation of the trial findings, inform implementation 
of the intervention on a wider scale (eg, other long- term 
conditions) and aid potential future implementation of 
the intervention.
Our objectives at each of the six process evaluation sites 
are to:
 ► Determine the degree to which the intervention is 
delivered (internal fidelity).
 ► Explore and explain the relationship between inter-
vention implementation and the trial outcomes.
 ► Identify barriers and facilitators for the successful 
implementation and roll out of the intervention 
(should the intervention be effective).
METHODS
Study design
In addition to the aforementioned MRC guidance,13 
we will draw on other relevant literature,16 17 in partic-
ular the Consolidated Framework for Implementation 
Research (CFIR).18 The CFIR is a conceptual framework 
that was developed to guide systematic assessment of 
multilevel implementation contexts to identify factors 
that might influence intervention implementation and 
effectiveness.19 The MaTI intervention is implemented at 
multiple levels at each site including trusts, secondary and 
primary healthcare professionals and patients. The CFIR 
framework generates a knowledge base for implementa-
tion across multiple settings within five major domains: 
intervention characteristics, inner setting, outer setting, 
individual characteristics and implementation process. 
Domains will be explored and additional relevant theo-
retical frameworks applied as appropriate. We will also 
draw on human resource management evaluation, specif-
ically the ability, motivation and opportunity (AMO) 
model,20 21 and capability, opportunity and motivation 
(COM- B) model.22 These models are complementary and 
highlight how policy interventions that require changes 
in staff behaviour are shaped by their ability to work in 
different ways, in terms of skills, their level of motivation 
and their opportunities to change practice.
The study design is a parallel mixed synthesis study 
using quantitative and qualitative data from six interven-
tion sites of the total 42 sites in the cluster randomised 
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controlled trial. Methods will involve non- participant 
observations, semi- structured interviews and surveys. In 
order to capture data on barriers and facilitators to imple-
mentation we will collect data from health professionals 
working along the patient pathway (from both secondary 
and primary care), patients and community pharmacists. 
We will also use fidelity data on adherence to MaTI that is 
being collected within each intervention site in the trial. 
We will explore and explain the relationship between 
intervention implementation and the trial outcomes in the 
six process evaluation sites through analysing secondary 
outcome data. These data will indicate whether the inter-
vention improves patient understanding of their medi-
cines and satisfaction with medicines- related care at 2 and 
6 weeks postdischarge and twelve months postregistration 
from the Patient Experience Survey (PES) (a validated 
item from Coleman et al’s transition measure23), along-
side observations and implementation data collected as 
part of the process evaluation. Process evaluations need 
to be flexible in the context of the ongoing trials they are 
evaluating and we will record and describe adaptations to 
this protocol when the findings are published.
Sampling and recruitment
We aim to purposively sample six intervention sites based 
on the following criteria:
 ► University and non- university hospitals.
 ► Method for transferring medicines discharge infor-
mation to community pharmacists’ for example, elec-
tronic system, post, telephone.
 ► Sites located across different geographic areas of 
England.
Within each of the six selected sites we will recruit 
patients and staff for interviews and surveys. We will also 
conduct observations at each of these sites. The sampling 
approach will be iterative and following sampling of one- 
to- two pilot sites; consideration of the initial data in rela-
tion to fidelity will be made.
Patient interviews
Twenty patients in total will be sampled for interviews 
(three to four patients across each of the six sites). We will 
adopt a purposive sampling strategy to meet our target 
characteristics in terms of gender, age, length of diagnosis 
and fidelity to intervention. After piloting, we may need 
to modify our approach to enable diversity in relation to 
our sampling criteria. Patients approached will be those 
that have participated in the trial and received the MaTI 
intervention.
Observations of intervention wards
We will seek permission to conduct non- participant obser-
vations of staff at ward level (two and a half hours per site). 
Staff members will be provided with information sheets 
and a script for informing patients of the researchers’ 
presence. A maximum of two researchers will be present 
at any one time. Staff will have the opportunity to opt out 
of the observation. A potential limitation of conducting 
overt observation is the Hawthorne effect by which indi-
viduals being observed may alter their behaviour because 
they are aware that they are being studied.24 We will seek 
to minimise the impact by informing staff that they are 
being observed and we wish them to behave as normal.25
Hospital staff interviews and surveys
Thirty hospital staff across six sites will be interviewed. 
Staff members will include those involved in delivering 
MaTI, such as heart failure specialist nurses, ward pharma-
cists, pharmacy technicians, cardiology ward nurses and 
site coordinators. We will identify and recruit secondary 
care staff through a combination of two approaches: (1) 
we will use information obtained during our ward obser-
vations about staff roles in delivering the intervention 
and approach staff directly and (2) we will also liaise with 
the appointed site coordinator to identify staff that are 
directly involved in the delivery of MaTI.
We will recruit hospital staff for surveys, aiming to 
recruit as many staff as possible involved in delivering 
MaTI. We will identify hospital staff with assistance from 
the site coordinators and seek informed consent from all 
staff.
Community pharmacist interviews and surveys
We will identify and recruit ten community pharma-
cists for interviews. Community pharmacists contacted 
through nominated pharmacies in each of the six sites 
will be interviewed. We will identity through the following 
two methods: the patient checklist forms (collected by 
the trials unit) containing details of the pharmacy used 
by patients in the trial; directly contacting and inviting 
community pharmacists to participate.
Surveys will be undertaken with community pharma-
cists involved in delivering the intervention. The number 
of surveys returned will be dependent on the number of 
differing community pharmacies patients have used as 
well as return rates. We will identify community pharma-
cists for surveys through the methods highlighted above 
for interviews.
Community heart failure nurse surveys
We will recruit up to five community heart failure 
nurses in each of the six evaluation clusters to complete 
surveys. A maximum of 30 surveys will be conducted in 
total. Community heart failure nurses will be identified 
through referrals made to the community heart failure 
services from the hospitals.
For all interviews and surveys, participants will be 
provided with an information sheet and informed, written 
consent will be obtained.
Data collection
Patient interviews
Semi- structured interviews with patients will be under-
taken in patients’ homes 3 months postregistration into 
the trial and will last approximately 45 min. Interviews, 
with patients and staff, will be audio recorded and tran-
scribed verbatim. (This protocol was agreed prior to 
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COVID-19. Data collection methods are being altered in 
response to the pandemic. For example, recent interviews 
are being conducted via phone. Our flexible approach 
to the protocol has facilitated these changes. Changes in 
methods will be tracked and reported as per pragmatic 
study development). In the first site, patient data will 
be collected in a block of three to four relatively early 
in the implementation of the intervention (in the first 
3 months). In subsequent sites, we may sample during 
middle and late phases of implementation which will 
be determined based on the data collected. As the trial 
progresses, we will become more familiar with how the 
intervention is being implemented. Interview schedules 
will include a range of questions, probes and prompts 
and will explore patient experiences of the intervention 
components.
Observations of intervention wards
Two researchers (CP/HI) will conduct unstructured and 
structured observations of clinical staff (heart failure 
nurses, cardiology nurses, cardiology pharmacists) 
of adherence to the intervention (content, coverage, 
frequency and duration). These observations will take 
place in hospital 6 months postregistration of the first 
patient recruited at that site, focusing in- depth on the 
discharge process and introduction of the MaTI toolkit. 
Observations will be two and a half hours per site designed 
to capture not only delivery of the MaTI (structured) but 
also to augment our understanding of the hospital ward 
culture and environment (unstructured). Focused and 
general observation data will be collected through the 
use of a designed structured observation tool and field 
notes.
The focus of the observations will be on the interac-
tion between staff and patients, particularly around the 
discharge process and completion/use of the toolkit. 
Other aspects of the intervention for example, transfer of 
information, time spent with patients and level of patient 
understanding will be observed if possible. We will collect 
quantitative data using structured observations to record 
actions or behaviours, for example, how information 
was introduced and provided to patients. The structured 
observation may pose a greater challenge to collect as 
it will not be possible to identify in advance when MaTI 
related activities, such as the introduction of the toolkit, 
will occur. The two- and- a- half- hour period of observa-
tion will be discontinuous. We will wait at the site until 
relevant activity occurs, and we will liaise with staff within 
the site to help us identify suitable times to conduct this 
structured observation. Staff will help us identify when 
the intervention- related activity is likely to occur. In 
the unstructured observations, we will seek to develop 
a more general understanding of the ward culture and 
the ways the staff interact with patients and each other 
in the delivery of care. Unstructured data will be collated 
through field notes.
Hospital staff interviews and surveys
Semi- structured interviews with hospital staff will be 
conducted using an interview schedule covering staff 
experiences in delivering the intervention. These will take 
place at the hospital and at the end of site trial implemen-
tation, that is, 2 weeks postdischarge of the last recruited 
patient to avoid influencing intervention implementation 
during the trial. Survey data will be collected through 
paper questionnaires provided to staff when visiting the 
hospital at the end of site implementation. A maximum 
180 surveys will be conducted.
Community pharmacist interviews and surveys
Community pharmacy semi- structured interviews will 
focus on how the pharmacists interacted with the 
enhanced communication from the hospital and how 
they engaged with patients post discharge. An interview 
schedule will be used to collect data on the interventions 
perceived usability and impact. These will take place at 
the end of site implementation, that is, 2 months post-
discharge of the last recruited patient. Interviews may 
take place face to face or via phone. Survey data will be 
collected through questionnaires to staff via post once 
the intervention has finished at that site. A maximum 300 
surveys will be conducted.
Community heart failure nurse surveys
Community heart failure nurses will be invited to 
complete postal surveys at the end of site implementation. 
A maximum 30 surveys will be conducted. We do not plan 
to interview community heart failure nurses because our 
primary focus is those delivering the intervention that is, 
hospital staff and community pharmacists. However, the 
survey data will explore whether nurses used the toolkit 
with patients in the community, whether the toolkit 
enhanced patient care and whether nurses would advo-
cate the use of the toolkit to support patient treatment. 
Table 1 illustrates the timing of all data collection.
Analysis
The qualitative analysis will be undertaken using a two- 
step process:
Step 1: framework analysis
The process of interpreting the transcripts will take place 
while interviews are still being conducted. This will give 
the research team the opportunity to explore emerging 
themes in detail in subsequent interviews. The interviews 
and unstructured observations will be analysed using the 
Framework approach, which involves detailed familiari-
sation with the data, identifying key themes, interpreting 
the findings within the context of similar research studies, 
and considering policy and practice.26 The emerging 
analysis will be thematic and iterative with regular discus-
sions taking place with the process evaluation team. This 
involvement will support our interpretation of the inter-
view data. The analysis will be theoretically informed by 
COM- B22 and AMO.20–22
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Step 2: CFIR
Following initial theme generation, we will review the 
data using the CFIR.18 The analysis will involve mapping 
barriers and facilitators onto domains within CFIR.
Quantitative data will include survey, structured obser-
vations and data on adherence to the intervention. The 
survey data will be entered into secure databases. Descrip-
tive statistics will be employed to analyse survey data. Data 
relating to adherence to MaTI is being collected from 
all intervention sites. This consists of checklists detailing 
which components of the intervention were implemented 
for each patient. We will use these data to inform and 
explain the findings in the process evaluation sites.
Additional data
Where appropriate, we may consider using the additional 
data (collected for all sites as part of the wider trial) to 
inform, explain and triangulate findings with the process 
evaluation. For example, we may decide that we need 
more structured information on completion of the MaTI 
checklist to consider alongside our staff interviews and so 
clarify which steps of the MaTI different staff members 
carried out.
Additional data sources include:
 ► Site Feasibility Questionnaire (initial questions sent 
to sites to assess their suitability to take part in the 
trial covering areas such as clinical pathways, staffing 
levels/ types of specialist staff, communication with 
community pharmacy and the number of patients).
 ► PES (completed by patients at 2 weeks/6 weeks/12 
months postdischarge).
 ► MaTI checklist completed in the hospital (moni-
tors adherence to the main components of the 
intervention).
 ► National Heart Failure Audit Data27 (reports on the 
characteristics of patients admitted with acute or 
subacute heart failure, in- hospital investigations and 
care, treatment given and the discharge planning and 
follow- up).
 ► Community pharmacy data collection form (describes 
implementation within community pharmacy).
Analysis will be integrative in order to clarify and explain 
the predominant systems and their implications; qualita-
tive and quantitative data will be consolidated through 
a process of ‘parallel mixed analysis’.28 This includes an 
independent analysis of the quantitative and qualitative 
data to provide an understanding of key phenomena and 
the two understandings will be integrated using meta- 
inferences. For example, key findings will be generated 
iteratively, explicitly supported by quantitative data (such 
as structured observational and survey data) and substan-
tiated or augmented by thematic qualitative data (such 
as interview data and field notes) and vice- versa. Survey 
data will be compared across the six clusters to identify 
any differences in staff perceptions of the barriers and 
facilitators to delivery. Analysis will be descriptive.
The combined analysis will, therefore, meet our key 
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implementation of the intervention on a wider scale (eg, 
other long- term conditions) and aid potential future 
implementation of the intervention. This will be achieved 
by providing an in depth understanding of the overall 
implementation, mechanisms of impact and external 
factors (infra structure) that may influence delivery and 
functioning of the intervention.
Patient and public involvement
The ISCOMAT study has a patient- led steering group that 
is involved in all stages of the research process, including 
the process evaluation. Due to the process evaluation’s 
iterative design we will regularly consult with the group via 
meetings and phone/email. The group will continue to 
be consulted on the research design, questions, outcome 
measures and findings. In particular the members of the 
group contribute to reviews and evaluations, as well as 
reading and considering study and consultation docu-
ments from a patient perspective. The group’s expertise 
through their experiences of living with heart failure will 
be crucial in understanding patients’ experiences with 
the MaTI intervention in particular.
ETHICS AND DISSEMINATION
The process evaluation has been approved as part of the 
ISCOMAT trial by the Research Ethics Committee and 
the UK Health Research Authority REC: 18/YH/0017/
IRAS: 231 431.
Findings will be disseminated via academic and policy 
conferences, peer- reviewed publications, social media, 
for example, Twitter, with further avenues for dissemina-
tion to be agreed on with our patient led steering group.
CONCLUSION
In this paper, we have described the design and methods 
for the mixed- methods process evaluation of the NIHR- 
funded ISCOMAT cluster randomised controlled trial 
which will test the effectiveness of a complex behavioural 
intervention aimed at improving medications manage-
ment at the interface between hospital and community 
for patients with hospitalised with heart failure. This 
process evaluation protocol demonstrates the importance 
of process evaluations for understanding outcomes in 
the clinical trial, as well as providing guidance for future 
process evaluations. We have followed the MRC recom-
mendations and guidance on the delivery of process 
evaluation13 in order to support the standardisation of 
process evaluations.
Author affiliations
1School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of 
Bradford, Bradford, UK
2Wolfson Centre for Applied Health Research, Bradford, UK
3Bradford Institute for Health Research, NIHR Yorkshire and Humber Patient Safety 
Translational Research Centre, Bradford, UK
4Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
5Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, 
Leeds, UK
6Leeds Institute for Data Analytics, University of Leeds, Leeds, UK
7Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
8Clinical Trials Research Unit, University of Leeds, Leeds, UK
9School of Healthcare, University of Leeds, Leeds, UK
Twitter Catherine Powell @CathPowell5, Chris P Gale @cpgale3 and David P 
Alldred @MedicinesDavid
Acknowledgements We would like to thank Alison Blenkinsopp, Gerry Armitage, 
Lauren Moureau, Jan Speechley, the ISCOMAT Patient- led Steering Group, the 
ISCOMAT Trial Management Group, Trial Steering Committee and the Programme 
Steering Committee.
Collaborators Our collaborators include members of the wider ISCOMAT 
Programme Management Team who contributed to previous work packages and 
the ongoing programme including: Jon Silcock, David K. Raynor, Robert Turner, John 
Wright, Ian Kellar, Roberta Longo, Ivana Holloway, Chris Bojke, Leeds Clinical Trials 
Research Unit.
Contributors CP, LB, BF, HI, SA, CG, PG, AF and DPA developed the detail of the 
process evaluation protocol. CP drafted the manuscript and all authors reviewed 
it critically for intellectual content and approved the final version submitted for 
publication.
Funding This study is funded by the National Institute for Health Research (NIHR) 
(Programme Grants for Applied Research (Grant Reference Number RP- PG-0514-
20009)). This research was supported by the National Institute for Health Research 
(NIHR) Yorkshire and Humber Patient Safety Translational Research Centre (NIHR 
Yorkshire and Humber PSTRC).
Disclaimer The views expressed are those of the authors and not necessarily 
those of the NIHR or the Department of Health and Social Care.
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting, or dissemination plans of this research. Refer to 
the Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Catherine Powell http:// orcid. org/ 0000- 0001- 7590- 0247
Liz Breen http:// orcid. org/ 0000- 0001- 5204- 1187
Beth Fylan http:// orcid. org/ 0000- 0003- 0599- 4537
Hanif Ismail http:// orcid. org/ 0000- 0002- 7885- 6648
Sarah L Alderson http:// orcid. org/ 0000- 0002- 5418- 0495
Chris P Gale http:// orcid. org/ 0000- 0003- 4732- 382X
Peter Gardner http:// orcid. org/ 0000- 0002- 8799- 0443
Amanda J Farrin http:// orcid. org/ 0000- 0002- 2876- 0584
David P Alldred http:// orcid. org/ 0000- 0002- 2525- 4854
REFERENCES
 1 Dewan P, Rørth R, Jhund PS, et al. Income inequality and outcomes 
in heartfailure: A global between- country analysis. JACC Heart Fail 
2019;7:336–46.
 2 British Heart Foundation. Uk Factsheet, 2020. Available: https://
www. bhf. org. uk/ what- we- do/ our- research/ heart- statistics [Accessed 
14 Apr 2020].
 3 Conrad N, Judge A, Tran J, et al. Temporal trends and patterns 
in heart failure incidence: a population- based study of 4 million 
individuals. Lancet 2018;391:572–80.
 4 Gho JMIH, Schmidt AF, Pasea L, et al. An electronic health records 
cohort study on heart failure following myocardial infarction in 
England: incidence and predictors. BMJ Open 2018;8:e018331.
 5 National Institute for Health and Social Care Excellence. Chronic 
heart failure in adults: diagnosis and management NICE guideline 
 on N
ovem









pen: first published as 10.1136/bm






7Powell C, et al. BMJ Open 2020;10:e040493. doi:10.1136/bmjopen-2020-040493
Open access
[NG106, 2018. Available: https://www. nice. org. uk/ guidance/ ng106 
[Accessed 14 Apr 2020].
 6 Phipps DL, Morris RL, Blakeman T, et al. What is involved in 
medicines management across care boundaries? A qualitative study 
of healthcare practitioners' experiences in the case of acute kidney 
injury. BMJ Open 2017;7:e011765.
 7 Urban R, Paloumpi E, Rana N, et al. Communicating medication 
changes to community pharmacy post- discharge: the good, the bad, 
and the improvements. Int J Clin Pharm 2013;35:813–20.
 8 Fylan B, Marques I, Ismail H, et al. Gaps, traps, bridges and props: 
a mixed- methods study of resilience in the medicines management 
system for patients with heart failure at hospital discharge. BMJ 
Open 2019;9:e023440.
 9 Inamdar A, Inamdar A. Heart failure: diagnosis, management and 
utilization. J Clin Med 2016;5:62.
 10 Van Spall HGC, Lee SF, Xie F, et al. Effect of patient- centered 
transitional care services on clinical outcomes in patients 
hospitalized for heart failure: the PACT- HF randomized clinical trial. 
JAMA 2019;321:753–61.
 11 Raynor DK, Ismail H, Blenkinsopp A, et al. Experience- Based co- 
design- Adapting the method for a researcher- initiated study in a 
multi- site setting. Health Expect 2020;23:562–70.
 12 Ellard DR, Taylor SJC, Parsons S, et al. The opera trial: a 
protocol for the process evaluation of a randomised trial of an 
exercise intervention for older people in residential and nursing 
accommodation. Trials 2011;12:28.
 13 Moore GF, Audrey S, Barker M, et al. Process evaluation of 
complex interventions: medical Research Council guidance. BMJ 
2015;350:h1258.
 14 Mann C, Shaw A, Guthrie B, et al. Protocol for a process evaluation 
of a cluster randomised controlled trial to improve management 
of multimorbidity in general practice: the 3D study. BMJ Open 
2016;6:e011260.
 15 Grant A, Treweek S, Dreischulte T, et al. Process evaluations for 
cluster- randomised trials of complex interventions: a proposed 
framework for design and reporting. Trials 2013;14:15.
 16 Ellard DR, Thorogood M, Underwood M, et al. Whole home exercise 
intervention for depression in older care home residents (the opera 
study): a process evaluation. BMC Med 2014;12:1.
 17 Sheard L, O'Hara J, Armitage G, et al. Evaluating the PRASE patient 
safety intervention - a multi- centre, cluster trial with a qualitative 
process evaluation: study protocol for a randomised controlled trial. 
Trials 2014;15:2282.
 18 Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation 
of health services research findings into practice: a consolidated 
framework for advancing implementation science. Implement Sci 
2009;4:50.
 19 Keith RE, Crosson JC, O'Malley AS, et al. Using the consolidated 
framework for implementation research (CFIR) to produce 
actionable findings: a rapid- cycle evaluation approach to improving 
implementation. Implement Sci 2017;12:15.
 20 Macky K, Boxall P. The relationship between ‘high- performance work 
practices’ and employee attitudes: an investigation of additive and 
interaction effects. Int J Hum Resour 2007;18:537–67.
 21 Purcell J. Understanding the people and performance link: unlocking 
the black box. CIPD Publishing, 2003.
 22 Michie S, van Stralen MM, West R. The behaviour change wheel: 
a new method for characterising and designing behaviour change 
interventions. Implement Sci 2011;6:42.
 23 Coleman EA, Mahoney E, Parry C. Assessing the quality of 
preparation for posthospital care from the patient's perspective: the 
care transitions measure. Med Care 2005;43:246–55.
 24 Roethlisberger F, Dickson W. Management and the worker 
Cambridge. MA: Harvard University Press, 1939.
 25 Campbell JP, Maxey VA, Watson WA. Hawthorne effect: implications 
for prehospital research. Ann Emerg Med 1995;26:590–4.
 26 Ritchie J, Lewis J, Nicholls CM, et al. Qualitative research practice: a 
guide for social science students and researchers. Sage, 2013.
 27 National Institute for Cardiovascular Outcomes Research (NICOR). 
National heart failure audit 2017/18. Available: https://www. nicor. 
org. uk/ national- cardiac- audit- programme/ heart- failure- heart- failure- 
audit/ [Accessed 25 Nov 2019].
 28 Creswell JW, Clark VLP. Designing and conducting mixed methods 
research. Sage publications, 2017.
 on N
ovem









pen: first published as 10.1136/bm
jopen-2020-040493 on 24 N
ovem
ber 2020. D
ow
nloaded from
 
